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heart disease. SPECT is most commonly used for clinical myocardial perfusion imaging, whereas PET
is the clinical reference standard for the quantification of myocardial perfusion. MRI does not involve
exposure to ionizing radiation, similar to echocardiography, which can be performed at the bedside. CT
perfusion imaging is not frequently used but CT offers coronary angiography data, and invasive catheter-
based methods can measure coronary flow and pressure. Technical improvements to the quantification
of pathophysiological parameters of myocardial ischaemia can be achieved. Clinical consensus recom-
mendations on the appropriateness of each technique were derived following a European quantitative
cardiac imaging meeting and using a real-time Delphi process. SPECT using new detectors allows the
quantification of myocardial blood flow and is now also suited to patients with a high BMI. PET is
well suited to patients with multivessel disease to confirm or exclude balanced ischaemia. MRI allows
the evaluation of patients with complex disease who would benefit from imaging of function and fibrosis
in addition to perfusion. Echocardiography remains the preferred technique for assessing ischaemia in
bedside situations, whereas CT has the greatest value for combined quantification of stenosis and char-
acterization of atherosclerosis in relation to myocardial ischaemia. In patients with a high probability
of needing invasive treatment, invasive coronary flow and pressure measurement is well suited to guide
treatment decisions. In this Consensus Statement, we summarize the strengths and weaknesses as well
as the future technological potential of each imaging modality.
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International guidelines advocate noninvasive testing 
for patients with suspected ischaemia before proceeding 
with revascularization decision- making1–4. Noninvasive 
clinical cardiac imaging continues to undergo rapid evo-
lution, focusing on quantitative perfusion technologies 
for the assessment of myocardial ischaemia and coronary 
flow. At present, imaging of myocardial ischaemia stands 
at a crossroads. During a European meeting on quan-
titative cardiac imaging, a bench- to- bedside- to- bench 
perspective was used to summarize the current status 
and future potential of myocardial ischaemia imag-
ing from the viewpoint of basic scientists and clinical 
researchers. This approach created discussions, which 
led to this Consensus Statement on the main advantages 
and disadvantages of each imaging modality, a clinical 
consensus on the appropriateness for specific indica-
tions and a summary of the latest developments, which 
together provide a framework for future quantitative 
imaging of myocardial ischaemia.
Pathophysiology considerations
The coronary circulation comprises the epicardial con-
ductance vessels (diameter 1–6 mm) feeding an exten-
sive network of small vessels (diameter <300–400 μm) 
that penetrates the cardiac muscle tissue and is the site 
of regulation of myocardial blood flow (MBF; Fig. 1a,b). 
High- resolution 3D fluorescence cryomicrotome imag-
ing5 has also revealed the existence of abundant small 
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collateral vessels both between (intercoronary) and 
within (intracoronary) perfusion territories of major 
coronary arteries6,7. Importantly, blood supply via 
well- developed collaterals can reduce the area of myo-
cardium at risk of ischaemia, which can be detected by 
all myocardial perfusion imaging techniques8–10. From 
a physiological perspective, microvascular resistance 
is closely adjusted at rest via integrated control mech-
anisms to maintain blood supply commensurate with 
cardiac workload and to compensate for pressure loss 
induced by an epicardial stenosis (autoregulation)11–13 
(Fig. 1c). When microvascular resistance is minimized 
by potent vasodilators, such as adenosine, coronary flow 
becomes primarily dependent on perfusion pressure. 
Given that vessels without tone behave as elastic con-
duits, their diameters become pressure- dependent, and 
the minimized coronary resistance (at maximal vasodil-
atation; Fig. 1c) increases with decreasing perfusion 
pressure14–16. Regional myocardial perfusion in normal 
tissue is highly heterogeneous, attributable to vascular 
(asymmetric branching) and metabolic (O2 consump-
tion) heterogeneity17,18. Transmural perfusion gradients 
and the microcirculation itself are further influenced by 
cardiac–coronary interaction with or without an epicar-
dial obstruction. Compressive forces exerted by cardiac 
contraction render the subendocardium particularly vul-
nerable to ischaemia, especially at elevated heart rate or at 
low perfusion pressure distal to a stenosis19–21. The effects 
of epicardial obstruction, therefore, extend beyond the 
stenosis into the microcirculation22. The fundamental 
parameters for the assessment of myocardial ischaemia 
are regional absolute MBF (in units of millilitres per min-
ute per gram of tissue) and relative perfusion, as well as 
relative parameters, such as myocardial perfusion reserve 
(MPR), which is the ratio of MBF under exercise- induced 
or pharmacologically induced stress to MBF at rest22.
Ischaemia imaging modalities
The potential of noninvasive assessment of blood flow in 
the coronary microcirculation as a gatekeeper for inva-
sive coronary angiography is the subject of a growing 
research effort. Important new insights have emerged 
regarding the clinical implications of the quantitative 
and qualitative assessment of myocardial ischaemia 
using the different myocardial perfusion imaging mod-
alities, such as SPECT, PET, MRI, echocardiography 
and cardiac CT. In addition to summarizing the cur-
rent clinical application of qualitative and quantitative 
ischaemia imaging, we also discuss the emerging possi-
ble use of artificial intelligence with deep learning for the 
detection and characterization of disease.
The unifying principle of all noninvasive techniques 
is that a contrast agent is injected into a peripheral vein. 
The contrast agent is transported to the heart and acts 
like a test substance (tracer) for blood and its transport 
through tissues. If the myocardium is normally per-
fused, the contrast agent is transported to the myocar-
dium and can be detected with the use of noninvasive 
imaging modalities. If ischaemia is present, less contrast 
agent reaches the affected region and/or its wash- in or 
wash- out is delayed. This process is typically registered 
by a dynamic series of images that are sensitive to the 
specific contrast agent used.
Subsequent tracer kinetic modelling16 gives quanti-
tative values of MBF and/or MPR. For this type of analy-
sis, we need to know the time course of the contrast 
agent or tracer in the blood over time, that is, the arterial 
input function (AIF). The AIF is typically assessed either 
from the left ventricular cavity or by arterial blood sam-
pling. From these principles, the AIF clearly accounts 
for variations in left ventricular function. However, col-
laterals cannot be accounted for and might introduce 
delayed wash- in23 and, on the basis of the mechanisms 
shown in Fig. 1d,e, might introduce systematic errors in 
the quantitative MBF or MPR values. Therefore, unlike 
catheter- based assessment and CT- based estimation 
of epicardial fractional flow reserve (FFR), the non-
invasive ischaemia imaging techniques directly measure 
MBF and MPR, or at least provide a semiquantitative 
estimate. Some of these techniques allow the additional 
assessment of parameters beyond MBF and MPR and 
are used in further analysis by modern methods, such 
as machine and/or deep learning24–27. The common 
goal is to guide patient management and to provide 
the requisite justification for invasive coronary angio-
graphy and intracoronary haemodynamic measure-
ments. Importantly, no single imaging technology can 
currently provide all measures of coronary circulation, 
and all imaging techniques have specific advantages and 
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disadvantages while also providing different assessments 
of the coronary vascular components using anatomical 
or functional imaging (Table 1).
Technical characteristics and challenges
Major practical challenges for the assessment of myocar-
dial ischaemia using the methods under consideration 
include the following:
•	 SPECT: radiation dose, spatial resolution and limited 
quantification of myocardial perfusion28.
•	 PET: lower spatial resolution of quantitative 15O-water 
PET than with myocardial CT or MRI perfusion 
imaging and limited visual assessment29,30.
•	MRI: increased prevalence of pacemakers31 and 
limited spatial coverage of the left ventricle32.
•	 Echocardiography: common presence of noise and 
artefacts, lack of reproducibility, variable image 
quality and time- consuming manual analysis33.
•	CT: limited temporal resolution, presence of beam 
and scatter artefacts, radiation dose, and low 
contrast- to- noise ratios34–37.
•	 Invasive FFR: diagnostic and prognostic character-
istics, complexity of the procedure and its limited 
uptake in clinical practice38,39.
From technical and pathophysiological perspectives, 
numerous aspects need to be considered for the quanti-
fication of myocardial ischaemia. The tracer distribution 
characteristics vary widely between imaging techniques. 
MRI and CT tracers enter the extravascular extracellular 
space (interstitial space); nuclear tracers can also enter 
the intracellular space or even bind within the myo-
cyte (most SPECT and PET tracers, except 15O-water) 
(Table 1). By contrast, microbubbles used for echocardio-
graphy remain in the intravascular space. On the basis 
of the different tracer characteristics, the agreement 
between the numerical results obtained with the differ-
ent techniques varies40–42. Even microspheres, which are 
the experimental gold standard of perfusion, can dis-
tribute in a heterogeneous manner when the analysed 
region becomes small, possibly reflecting technical limi-
tations and/or physiological variations in regional flow43. 
A nonlinear relationship exists between MBF and tracer 
uptake in SPECT and most PET tracers except 15O- water. 
Both MRI and CT use contrast agents that extravasate 
from the intravascular to the extravascular space in a 
fashion that is nonlinearly dependent on blood flow44. 
In addition, obtaining a linear relationship between 
MRI tracer concentration and signal intensity is diffi-
cult because of the complexity of MRI contrast mecha-
nisms45,46. Accurately measuring the AIF is challenging 
with SPECT47, PET48, MRI49,50 and CT51 (Fig. 1c,d), which 
can result in biased measurements of MBF (Fig. 1e). 
Tracer kinetic modelling of MBF needs to account for 
these differences between modalities.
Methods of consensus
The emerging imaging concepts and their challenges 
matter not only to cardiologists, radiologists and nuclear 
medicine physicians but also to non- specialists. As the 
field has become very complex, it deserves a compre-
hensive and up- to- date expert consensus. Experts in the 
cardiac imaging modalities from seven European coun-
tries, with a balance of clinical disciplines (cardiology, 
nuclear medicine and radiology) and basic scientists, 
were involved in the Quantitative Cardiac Imaging meet-
ing. This Consensus Statement is not, therefore, endorsed 
by a single specialist society, but is driven by scientists 
from all disciplines collaborating to provide a multidis-
ciplinary consensus. The content and recommendations 
in this article emerged from discussions among our 
diverse team, which aimed to overcome political and 
professional interests to produce balanced consensus 
recommendations. In a subsequent real- time Delphi 
process, the technical parameters of each modality 
were summarized by consensus (Table 1).
All the authors participated in the Delphi process and 
judged all imaging modalities, to result in a consensus 
across modalities. The consensus process was performed 
after all lectures were given and discussed during the 
Quantitative Cardiac Imaging meeting and was organ-
ized into technical and clinical consensus processes. 
During the technical consensus process (Table 1), a total 
of 20 authors participated (six cardiologists: K.F.K., A.C., 
P.K., R.S., J.J.P. and T.v.d.H.; four radiologists: M.D., 
K.N., R.M. and F.M.; one dual cardiologist–radiologist: 
P.M.- H; one nuclear medicine physician: F.B.; and eight 
methodologists: M.S., M.K., S.K., T.S., S.N., M.L., J.M. 
and L.S.). Technical assessments by every participant 
for all items were made transparent to all participants to 
allow real- time evaluation and reconsideration of his or 
her own judgements for the Delphi consensus process.
For the clinical consensus process (Fig. 2), a total of 
16 authors participated and were divided into a devel-
opment team and a clinical appropriateness team. The 
development team consisted of eight investigators (one 
dual cardiologist–radiologist: P.M.- H.; two radiologists: 
K.N. and F.M.; and five methodologists: M.S., T.S., A.K., 
J.M. and L.S.), who did not participate in the clinical appro-
priateness rating but defined the questions and categories 
used in the clinical consensus. The clinical appropriateness 
team consisted of eight investigators providing clinical 
consensus ratings for all methods and all clinical scenarios 
(four cardiologists: K.F.K., A.C., R.S. and J.J.P.; two radiol-
ogists: M.D. and R.M.; one nuclear medicine physician: 
F.B.; and one methodologist: M.L.). Judgements from 
each team member were fully taken into consideration, 
displayed in a transparent fashion during the real- time 
Delphi process and averaged at the end of the assess-
ment to produce final appropriateness ratings (ranging 
from 1 to 9) for all imaging tests in all clinical settings.
Moreover, in this Consensus Statement, we avoided 
giving the final verdict on a ‘competition between the 
methods’, but instead presented the potential relative mer-
its of the methods that are currently available. Differences 
of opinion will always exist, which cannot entirely be 
avoided, but our cross- disciplinary Delphi process repre-
sents a solid approach to the clinical question. This Delphi 
process helped to define appropriate clinical indications 
as well as some of the directions for future technical devel-
opments to overcome challenges of SPECT, PET, MRI, 
echocardiography, CT and invasive coronary flow and 
pressure measurements. This Consensus Statement also 
describes major trends and breakthroughs relevant to 
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patients with cardiac disease for all six imaging modal-
ities in the sections below. Although we attempt to give a 
balanced overview of all the available imaging modalities 
using the Delphi consensus process, region- specific or 
institution- specific availability or expertise might increase 
or decrease the relative utility of a particular modality.
SPECT
Role in assessment of ischaemic heart disease. SPECT 
has been the centrepiece of clinical cardiovascular imag-
ing for decades. SPECT- based evaluation of the extent 
of myocardial ischaemia as a percentage of the left 
ventricular myocardium, together with concomitantly 
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measured left ventricular function and volumes, is well 
established for the diagnosis of myocardial ischaemia1. 
SPECT not only has incremental prognostic value over 
clinical assessment alone but is also important in guiding 
therapy. The current clinical paradigm that the degree 
of ischaemia defines the individual risk, which in turn 
should be used for risk- based decision- making on revas-
cularization or optimized medical therapy, is based on 
large registries of SPECT perfusion imaging52. Of note, 
no studies have compared outcomes when therapy is 
decided on the basis of SPECT versus an alternative 
test. As SPECT measures any perfusion to the myocyte 
with a tracer that is bound in the mitochondria, and 
owing to the temporal resolution, a distinction between 
primary- vessel and collateral flow cannot be made.
Quantitative assessment of pathophysiology. Detailed 
technical characteristics of SPECT are listed in Table 1. 
Technical evolution has occurred, with the aim of max-
imizing sensitivity to reduce both the amount of injec-
ted radiopharmaceuticals and the acquisition time. 
These advances have been paralleled by a shift towards 
increased BMI in the patient population. Solid- state 
detector technology based on cadmium–zinc–telluride 
(CZT) has been central to the technical advances in 
SPECT imaging. Small semiconductor detectors allow 
fully digital acquisition schemes and obviate the need 
for heavy sodium iodide crystals and large photomulti-
pliers, thereby enabling compact camera designs (Fig. 3a). 
The high sensitivity (84%) of recent CZT SPECT sys-
tems and a specificity of 69% to detect obstructive cor-
onary artery disease53 has enabled dynamic imaging 
to assess the kinetics of perfusion tracers in blood and 
the myocardium. This information allows compart-
mental modelling to delineate absolute MBF and cor-
onary flow reserve (CFR) by SPECT. Recent work has 
shown the feasibility of MBF quantification with CZT 
SPECT and has provided validation against the micro-
sphere gold standard in an experimental model54 and in 
humans55 compared with PET. Clinically implementing 
this approach with SPECT protocols has the potential 
to provide incremental diagnostic and prognostic value 
for ischaemia assessment over the previous standard 
of relative regional perfusion defect measurement56,57, 
because it can detect conditions that affect the entire 
myocardium, such as severe ischaemia in multivessel 
disease or microvascular dysfunction (mostly in the 
subendocardium), with the caveat of the limited spatial 
resolution of SPECT. Therefore, integrating measures of 
transient post- ischaemic dilatation further improves the 
diagnostic accuracy and can be calculated in a highly 
automated fashion58.
Indications and clinical applications. SPECT is most 
commonly applied for myocardial perfusion imaging. 
Clinical indications for SPECT are listed in detail in 
Fig. 2. Major advantages of dedicated cardiac SPECT 
cameras include superior sensitivity and resolution 
while allowing radiation dose reduction across a range 
of patient conditions, as well as allowing the imaging of 
patients with challenging features, such as a high 
BMI59,60. Compared with regular SPECT, CZT systems 
increase the effective sensitivity by fourfold to tenfold, 
and also provide higher spatial and energy resolution59,60. 
Accordingly, high- quality images are obtained with 
shorter acquisition times and/or a smaller injected dose 
of the radiopharmaceutical, which is beneficial for vari-
ous groups of patients with complicated disease. Several 
multicentre studies support the usefulness as well as the 
diagnostic and prognostic value of CZT- based myocar-
dial perfusion SPECT28. Although early work with these 
novel systems focused on the reduction in imaging time 
from 15–30 min with standard SPECT down to 2–3 min 
with CZT SPECT using a standard amount of injected 
radioactivity61,62, the aim of subsequent work was to 
reduce the amount of injected radioactivity to minimize 
patient exposure to ionizing radiation. A recent multi-
centre trial suggests that CZT imaging can be completed 
with an effective dose of 1 mSv at an image quality that 
is still superior to that obtained with standard SPECT63.
Future developments. Commercially available software 
tools for SPECT analysis can be readily implemented 
on every acquisition system, allowing reproducible 
Fig. 1 | Interaction between coronary anatomy and physiology in relation to tracer 
distribution. a | Coronary arteries (left panel) penetrating the myocardium at the 
mid- ventricular level in a 3- mm- thick transverse section, as reconstructed from a 3D 
stack of cryomicrotome images5. The middle panel shows a magnified portion of the 
transmural microvascular network , as indicated by the red square in the left panel. 
Terminal arterioles perfusing the capillary bed are shown in the right panel.  
b | 3D reconstruction of coronary arteries and arterioles perfusing the heart muscle.  
c | Schematic illustration of the coronary pressure–flow relationship. Autoregulation 
maintains coronary flow at rest (green line) over a wide pressure range at a level adapted 
to oxygen consumption, whereas maximal flow without control (blue line) depends on 
coronary perfusion pressure. The zero- flow intercept incorporates collateral flow and 
depends on heart rate and ventricular wall tension1. In unobstructed vessels (black 
dashed line), flow increases with only negligible pressure loss at maximal vasodilatation. 
An epicardial stenosis induces progressive pressure loss with increasing flow (red dashed 
lines; stenosis severity increasing from top to bottom) and thereby raises minimal 
microvascular resistance. Stenosis resistance can be compensated at rest by lowering 
arterial tone, but limits maximal flow and compromises coronary flow reserve.  
d | Bolus- based perfusion methods such as MRI and CT typically obtain the arterial input 
function (AIF) from an easily visible anatomical region, such as the left ventricle (AIFLV). 
When tracer is transported along the epicardial vessels, the duration of the bolus 
increases (bolus dispersion). The upper part of the panel depicts a simulation of 
computational fluid dynamics that affect a vessel similar to that within the dashed 
rectangular region in part b50. Here, the assumption of a DOTA chelate- based tracer  
is made, which is injected quickly. For visualization purposes, simulations for the upper 
panel were made with a bolus 100 times shorter than that typically used in patients.  
See Supplementary Videos 1 and 2 for the dynamics. The lower panel shows the results 
from simulations of a real bolus, as used in humans. Similar bolus dispersion effects are 
expected for other tracers, depending on their diffusivity. The lower panel demonstrates 
that different regions (outlets 1–4) are exposed to slightly different AIFs (colours denote 
the different outlets in the upper part of the panel). If the observed bolus dispersion 
effects are not accounted for, a systematic underestimation of myocardial blood  
flow (MBF) of up to 45% can occur at rest, even in normal epicardial vessels without  
a stenosis135. The tissue curve is a typical concentration–time curve of the amount of 
tracer contained within a region of interest. For better visualization, the curve is scaled in 
amplitude by a factor of ten. The duration and shape of the curves depend on MBF. Tracer 
kinetic modelling of curves incorporates the AIF and results in a quantitative MBF value 
for that region. e | Tracer bolus broadening in a stenosed vessel. In addition to the bolus 
broadening in the normal epicardial vasculature, a stenosis increases the resistance and 
further disturbs bolus transport. Both effects depend on the shape and location of the 
stenosis (arrows), which results in additional bolus broadening and underestimation of 
MBF185. Pa, aortic pressure; Pb, extrapolated back pressure. Part e adapted with permission 
from reF.185, Wiley- VCH.
◀
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Table 1 | Technical comparison of tools for the assessment of myocardial ischaemia
Parameter SPECT PET MRI Echocardiography CT Invasive coronary 
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measurement of perfusion defect sizes and ventricular 
function (Fig. 3b). These tools also enable registration 
and fusion of SPECT datasets with coronary CT angiog-
raphy for improved prediction of long- term outcomes64 
(Fig. 3c) and the latest developments provide options 
for the absolute quantification of MBF from dynamic 
datasets (Fig. 3d) and the integration of artificial intelli-
gence techniques24,65. Future work will define how this 
comprehensive toolbox of quantitative parameters is 
best utilized in the work- up of myocardial ischaemia 
for guidance of targeted coronary interventions of the 
correct coronary artery, for the selection of coronary 
artery bypass grafting versus stenting versus optimal 
medical therapy alone, and for serial monitoring of the 
effects of therapy.
In summary, cardiac SPECT has advanced through 
the adoption of solid- state detector- equipped dedicated 
cameras as the new standard. This implementation ena-
bles fast assessment of myocardial perfusion and function 
with exposure to a low dose of radiation, and includes 
diagnostic and prognostic measures of relative regional 
ischaemia that are well established and quantitative. The 
next phase will include the quantification of MBF and 
CFR. The techniques are readily adopted from PET as 
the reference standard and can be translated to the field 
of SPECT owing to the increased sensitivity and the 
improved temporal resolution of the new cardiac camera 
systems. On the basis of its characteristics, SPECT is the 
primary clinical method for the assessment of myocar-
dial ischaemia, and the latest technological advances now 
also allow robust imaging of patients with challenging 
features, such as those with a high BMI.
Key points for SPECT. 
•	 SPECT is most commonly used in the clinic for 
myocardial perfusion imaging.
•	Challenges of SPECT include radiation dose and 
limited quantification of myocardial perfusion28.
•	Dedicated cardiac SPECT cameras have emerged, 
with improved sensitivity and resolution at lower 
radiation doses and in patients with challenging 
features (including those with a high BMI)59,60.
•	Quantitative measures of the perfusion defect size 
have become more widely available as diagnostic 
and prognostic markers with the introduction of 
solid- state detector CZT technology.
•	Dynamic imaging enables compartmental modelling 
and provides absolute measures of myocardial ischae-
mia, thereby bringing SPECT closer to PET as the 
reference standard.
PET
Role in assessment of ischaemic heart disease. PET 
is an inherently quantitative imaging technique that 
allows the accurate measurement of radioactivity con-
centrations in vivo, making PET the primary test for 
patients with multivessel disease to confirm or exclude 
balanced ischaemia. Currently, four different PET trac-
ers are used clinically for the assessment of MBF: 82Rb, 
13N- ammonia, 15O- water and 18F- flurpiridaz66. On 
the basis of close to 100% extraction, 15O- water PET 
is considered the clinical gold standard for perfusion 
quantification given that the image signal is directly 
proportional to tracer concentration, and tracer kinetic 
modelling is well established. All other tracers show 
a varying decrease in extraction with increasing flow, 
requiring correction to derive MBF (Fig. 4a). Because 
of their short half- lives, 82Rb and 15O- water allow the 
completion of rest–stress protocols within 30 min, with 
a total radiation dose that is lower than that of SPECT, 
although new SPECT technologies considerably reduce 
the radiation dose, as described above.
Quantitative assessment of pathophysiology. Detailed 
technical characteristics of PET are listed in Table 1. 
Because 15O- water is freely diffusible, no simple static 
uptake PET images are available for visual assessment, 
and images of perfusion defects are sometimes grainy 
and difficult to interpret. Therefore, quantification is 
needed for clinical assessment using 15O. With 82Rb, 
13N- ammonia and 18F- flurpiridaz, perfusion defects 
are visualized in a similar way to SPECT, but abso-
lute MBF measurements can be provided using tracer 
kinetic modelling and correction for limited extraction. 
Table 1 (cont.) | Technical comparison of tools for the assessment of myocardial ischaemia
Parameter SPECT PET MRI Echocardiography CT Invasive coronary 
flow and pressure 
measurement
Advantages and disadvantages
Advantages Wide availability 
and quantification 
now also possible in 
patients with a high 
BMI
Technically 
best- suited test 
for ischaemia 
quantification; 
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Limited use in 
patients without 
acute presentation
Consensus ratings were performed using a Delphi process with ratings by 20 investigators (six cardiologists, four radiologists, one dual cardiologist–radiologist, 
one nuclear medicine physician and eight methodologists). NA , not applicable.
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However, absolute measures remain variable, and a lack 
of standardization exists between systems. The complex-
ity of quantitative data analysis has long hampered the 
clinical feasibility of 15O- water PET. However, advances 
in scanner technology, image reconstruction methods 
and data analysis during the past decade have enabled 
nearly automated and fast computation of parametric 
images showing MBF at the voxel level and have facil-
itated the use of 15O- water in the clinical setting29,30. 
Another disadvantage of the lack of uptake images using 
15O- water is that myocardial function and volumes can-
not easily be quantified. Estimating ejection fractions 
from gated first- pass images has been shown to corre-
late well with values derived from MRI30,67. An advantage 
of the free diffusibility of 15O- water is that it allows the 
calculation of the perfusable tissue fraction, which is 
the ratio between uptake and clearance rate constants. 
Normalizing this parameter for the anatomical tissue 
fraction gives the perfusable tissue index, which is a 
marker of myocardial viability68,69. Therefore, MBF, via-
bility and functional parameters can now be determined 
from a single 15O- water PET scan (Fig. 4b).
Indications and clinical applications. Myocardial per-
fusion PET is increasingly being used for the evaluation 
of patients with known or suspected myocardial ischae-
mia. Clinical indications for PET are listed in detail in 
Fig. 2. The vast majority of studies have been conducted 
with static uptake images of 82Rb and 13N- ammonia. 
In a pooled analysis of these studies, weighted sensi-
tivity, specificity, negative predictive value and pos-
itive predictive value were 91%, 86%, 81% and 93%, 
respectively70. However, almost all these studies com-
pared PET with invasive coronary angiography with-
out invasive coronary flow or pressure measurement71. 
For such indirect detection of obstructive epicardial 
stenosis, PET is as accurate as CT or MRI perfusion 
imaging72,73. In addition, mounting evidence indicates 
that quantitative analysis of PET is superior to static- 
uptake image grading74–76. Even more compelling are the 
observations that hyperaemic MBF quantification out-
performs PET- derived CFR in the diagnosis of obstruc-
tive coronary artery disease, highlighting the potential 
of stress- only protocols77,78. Unfortunately, reported 
thresholds of what should be considered pathological 




























































Specific indications: effect on patient management
Potential for pathophysiological evaluation
Availability of technique in clinical practice 8 4 6 7 8 8
Suspected ischaemic heart disease:
non-acute symptomatic presentation
7 8 7 6 7 7
Suspected ischaemic heart disease:
acute symptomatic presentation
3 3 4 6 6 7
Technique is commonly applied in clinical practice 8 5 6 7 7 7
Technique includes quantification in clinical practice 5 8 4 3 4 6
Technological potential for ischaemia quantification 6 9 7 5 6 7
Coronary anatomy 6 6 7 5 9 9
Plaque morphology 2 2 4 1 9 2
Plaque composition 2 3 4 1 8 2
Haemodynamic relevance 6 7 7 5 5 7
Microcirculation 4 8 7 4 4 4
Perfusion 7 8 8 6 6 4
Absolute quantification of perfusion 4 9 6 3 5 3
Relative quantification of perfusion 8 9 7 5 6 6
Simultaneous myocardial wall-motion testing 7 7 7 8 5 6
Transmural extent of ischaemic defects 5 7 8 4 6 2
Cost-effectiveness of technique: patient perspective 7 5 7 8 6 6
Cost-effectiveness of technique: societal perspective 7 5 6 7 6 6
General adverse events profile 7 7 7 8 7 7
General level of evidence for assessment of
ischaemic heart disease
8 8 8 7 7 8
Patient acceptancea 7 8 6 8 8 6
Suspected ischaemic heart disease: risk stratification 8 8 7 7 7 6
Known ischaemic heart disease: risk stratification 8 8 7 6 7 6
Status after percutaneous coronary revascularization 6 7 5 6 5 8
Status after coronary surgery 5 7 6 5 6 7
Female sex 5 7 8 7 7 6
Heart failure 5 5 7 6 6 5
Microvascular dysfunction 4 8 7 5 3 3
High BMI 6 7 6 4 6 7
High heart rate 8 8 6 6 3 8
Young age 4 4 8 8 5 4
Potential for detection of secondary findings
or differential diagnosis
4 4 7 5 8 2
Known ischaemic heart disease:
non-acute symptomatic presentation
7 7 8 7 6 8
Known ischaemic heart disease:
acute symptomatic presentation
3 2 3 6 5 7
Known ischaemic heart disease:
balanced ischaemia in multivessel disease
4 8 6 5 5 7
Frequency of myocardial ischaemia examinations
per modality
8 4 5 6 5 8
Fig. 2 | Clinical characteristics and appropriateness  
of myocardial ischaemia assessment tools for  
different patient scenarios. Consensus ratings were  
on a scale of 1–9, with 1–3 being inappropriate, 4–6 being 
uncertain and 7–9 being appropriate. A total of 16 
investigators participated. A Delphi clinical consensus 
process was used, with ratings by eight participants  
(four cardiologists, two radiologists, one nuclear 
medicine physician and one methodologist). A separate 
development team of eight investigators (one dual 
cardiologist–radiologist, two radiologists and five 
methodologists) defined the questions and categories 
shown in the table but did not participate in the clinical 
appropriateness rating. aStudies discussed during the 
meeting showed higher patient acceptance for CT than 
for SPECT, MRI or invasive testing186–188.
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tracers22. Cut- off values seem to be, at least in part, 
related to tracer kinetics and should not be considered 
interchangeable.
In a contemporary study, PET had higher accuracy 
(85%) than coronary CT angiography (74%) or SPECT 
(77%) for the diagnosis of myocardial ischaemia when 
taking FFR as a reference standard40 (Fig. 4c). The com-
parative accuracy of PET versus CT or MRI perfu-
sion, which have higher spatial resolution, remains 
to be determined. In terms of prognosis, analogy to 
large- scale SPECT databases exists79. The extent and 
severity of (reversible) perfusion defects documented 
with PET hold strong prognostic information beyond 
that obtained from traditional cardiovascular risk 
factors22. PET- derived CFR has shown added prog-
nostic value for the identification of at- risk women 
with more frequent non- obstructive coronary artery 
disease and potential microvascular dysfunction57. 
Of particular interest is that apparently normal perfu-
sion images with a homogeneous tracer distribution 
• New (solid-state) detectors
• Dedicated cardiac cameras
• High sensitivity
• Fast imaging
• Low-dose radiation (<1 mSv)
a  SPECT
c  Fusion with CT angiography d  Dynamic imaging: absolute myocardial flow




LV function and dyssynchrony
Fig. 3 | SPECT for quantification of myocardial ischaemia. a | Design of a new , dedicated cardiac SPECT camera  
with static solid- state detectors focused on the heart, with the major characteristics summarized below the image.  
b | Representative images of current state- of- the- art SPECT measurements, including static images along the cardiac 
axes (top left), polar maps and segmental scores for quantification of defect size (bottom left), quality- control screens for 
CT- based attenuation correction of SPECT images (top right) and volumetric information on left ventricular (LV) function 
and synchrony from electrocardiogram (ECG)- gated images (bottom right). c | Advanced methodology for 3D fusion of  
a SPECT dataset with coronary CT angiography , enabling localization of ischaemia to a coronary artery territory. This 
image shows anterior wall ischaemia resulting from chronic occlusion of the left anterior descending coronary artery.  
d | Advanced analysis of dynamic SPECT images for absolute quantification of myocardial blood flow , including region- 
of- interest placement for myocardium and blood pool (top), derivation of time–activity curves (middle) and parametric 
display of flow parameters derived from compartmental modelling (bottom), including correction for tracer- specific 
nonlinear flow and extraction (see Fig. 4a).
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can be reclassified on the basis of diffusely blunted 
hyperaemic MBF or CFR; several studies have shown 
that this subset of patients is at increased risk of future 
cardiac events80–82.
Future developments. Both 15O- water and 13N- ammonia 
require the presence of an on- site cyclotron as a high 
upfront investment because of the short half- lives of 
both tracers (2 min and 9 min, respectively). By contrast, 



















































MBF rest MBF stress
Viability Blood volume
Fig. 4 | PET for quantification of myocardial ischaemia. a | Tracer signal versus myocardial blood flow (MBF), showing  
a constant 100% extraction for 15O- water, an almost 100% extraction for 13N- ammonia K1 and 
18F- flurpiridaz, and a 
substantial roll- off phenomenon, resulting in underestimation of MBF that increases with MBF, for 13N- ammonia  
(when quantified using its net influx rate), 201Tl- SPECT, Gd- DOTA dynamic contrast- enhanced (DCE) MRI, 82Rb and 
99mTc- MIBI- SPECT66,189–192. Note that the 82Rb and 99mTc curves overlap. b | MBF images at rest and during stress, myocardial 
viability and blood volume from a single rest–stress 15O- water protocol. This protocol can be used to assess ventricular 
volumes and ejection fraction. c | Example images from the PACIFIC trial showing coronary CT angiography (CCTA), 
SPECT, PET and invasive coronary angiography (ICA) images, with corresponding fractional flow reserve (FFR), in three 
patients (numbered 1–3) with coronary artery stenosis (arrows).
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82Rb (with a half- life of 1.3 min) is produced by a gener-
ator that has to be replaced on a monthly basis, which 
confers a high monthly cost but a low upfront invest-
ment. So- called baby cyclotrons have lower cost and are 
aimed specifically at the production of 13N or 15O and, 
therefore, also require lower energies and considerably 
less radiation shielding than common PET cyclotrons. 
This feature greatly increases the possibility of using 
15O- water and 13N- ammonia in hospitals without PET 
chemistry facilities. 18F- flurpiridaz is a novel tracer 
that has shown higher accuracy than SPECT83 and also 
promises quantification using direct parametric recon-
struction84. Furthermore, machine learning used for the 
integration of variables has great potential in clinical prac-
tice for identifying patients with myocardial ischaemia 
and increased risk of events25.
In summary, cardiac PET is the reference standard 
for the quantification of perfusion imaging. PET using 
parametric images showing MBF at the voxel level is now 
available in routine clinical practice, and PET also allows 
the derivation of the perfusable tissue index, which is a 
marker of myocardial viability, thereby expanding the 
clinical utility of this modality. On the basis of its charac-
teristics, PET is well suited for patients with multivessel 
disease to confirm or exclude balanced ischaemia, and 
low- cost baby cyclotrons will improve the cost- effective 
use of PET.
Key points for PET. 
•	 PET is the clinical reference standard for the quanti-
fication of myocardial perfusion.
•	Challenges of PET use include limited visual assess-
ment of quantitative 15O- water PET and the lower 
spatial resolution of PET compared with CT or MRI 
perfusion imaging29,30.
•	 Small or 13N- ammonia cyclotrons, as well as the 
availability of 18F- labelled tracers, could improve 
the cost- effectiveness of cardiac PET imaging, as well 
as logistics and dissemination.
•	Quantitative measures of myocardial ischaemia are 
provided with the addition of the measurement of 
viability and functional parameters during a single 
scan.
•	Hybrid imaging combining PET perfusion imaging 
with coronary CT angiography data might provide 
comprehensive assessment, especially in patients 
with multivessel disease.
MRI
Role in assessment of ischaemic heart disease. Since its 
inception85, myocardial perfusion MRI has evolved into 
a clinical modality with excellent sensitivity and speci-
ficity for detecting myocardial ischaemia86. Most clini-
cal myocardial perfusion MRI approaches are based on 
dynamic contrast- enhanced imaging using exogenous 
gadolinium- based contrast agents. The absence of ion-
izing radiation and the increasing availability of MRI 
expertise and equipment promote its routine use to 
guide clinical interventions. All components of a com-
prehensive MRI examination (that is, ventricular func-
tion and late gadolinium enhancement for viability and 
perfusion) add synergistic information to prognosis87,88. 
Long- term follow- up data have demonstrated a strong 
and independent predictive value of myocardial perfu-
sion MRI for future major adverse cardiac events and 
death89,90. The MR INFORM study91 demonstrated 
that, among patients with stable angina and risk fac-
tors for coronary artery disease, the use of myocardial 
perfusion MRI was associated with a lower incidence 
of coronary revascularization than the use of FFR and 
was non- inferior to FFR with respect to major adverse 
cardiac events.
Quantitative assessment of pathophysiology. Detailed 
technical characteristics of MRI are listed in Table 1. 
Although mostly visual or semiquantitative assessment 
is used to identify ischaemia in the clinic92, quantitative 
approaches93 have gained momentum with technical 
advances in MRI data acquisition, reconstruction and 
processing45,94. Quantitative perfusion analysis provides 
incremental prognostic value over semiquantitative and 
qualitative data analysis, with an area under the receiver 
operating characteristic curve (AUC) of 0.85 versus 0.75 
(reF.88). Figure 5a summarizes the technical approaches 
used for qualitative, semiquantitative and quantitative 
MRI perfusion. Although imaging is typically performed 
by acquiring three 2D sequences along the short axis 
in a dynamic fashion, the feasibility of dynamic 3D, 
whole- heart imaging has been shown32. The conver-
sion of signal intensity to contrast concentration is an 
important step for quantitative assessment (Fig. 5a). This 
process involves nonlinear mapping and dual sequence 
or dual bolus approaches to derive AIF95–97. In practice, 
a model- free Fermi function model has been widely 
used, and provides high accuracy and precision98 (Fig. 5a). 
Compared with Fermi models, distributed parameter 
models offer increased sensitivity (78% versus 96%) 
and specificity (88% versus 92%) by providing addi-
tional insights into changes in the permeability surface 
area and interstitial volumes evaluated99. Automated 
voxel- wise quantification offers faster assessment than 
the manual quantification of perfusion but has similar 
accuracy100. However, absolute measures remain vari-
able because they are tightly connected to the MRI 
sequence, and a lack of standardization exists between 
systems41. An automated method for AIF detection on 
the basis of pixel thresholding reduces analysis time 
and produces similar MBF values to those derived from 
manual AIFs101.
Indications and clinical applications. MRI is less com-
monly used than SPECT but avoids ionizing radiation 
and allows the evaluation of patients with complex 
disease, who benefit from quantification of function, 
fibrosis and perfusion. Clinical indications for MRI are 
listed in detail in Fig. 2. Myocardial perfusion MRI has 
advanced substantially, with improved temporal reso-
lution and the capacity to offer online automatic quan-
tification in millilitres per gram per minute. The most 
important clinical application of absolute myocardial 
perfusion quantification is in patients with complex 
disease to address questions about multivessel dis-
ease, microvascular dysfunction102 or a combination 
of both103. Quantitative perfusion is also feasible in 
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patients with heart failure and remodelled and thinned 
left ventricular walls, on the basis of the elevated spa-
tial resolution allowed by cardiac MRI104. Methods for 
combined assessment of quantitative perfusion and left 
ventricular scar have been described105. T1 mapping 
can be used to differentiate between obstructive disease 
and microvascular dysfunction with higher accuracy 
than perfusion MRI and has produced similar mapping 
results in infarcted and ischaemic tissue106. In the large, 
single- centre CE- MARC study107, the AUC for perfusion 
MRI (0.89) was higher than that for SPECT (0.74) on 
the basis of visual assessment. This finding is in agree-
ment with the secondary end points of the multicentre 
MR- IMPACT II study108 (Fig. 5b). However, quantitative 
MRI assessment in this study did not improve accu-
racy109, and the randomized, multicentre CE- MARC 2 
study110 showed equal reductions in unnecessary inva-
sive coronary angiography procedures using a diagnostic 
strategy on the basis of either MRI or SPECT. Compared 
with PET, quantitative perfusion MRI had a similar AUC 
of 0.83 for the detection of clinically significant coronary 
artery disease, but MRI perfusion values correlated only 
weakly with quantitative PET perfusion values, suggest-
ing that further refinements are necessary111 (Fig. 5b). 
This refinement could be possible with perfusion map-
ping MRI, which has been shown to result in higher 
correlation with 13N- ammonia PET112 (Fig. 5b). However, 
most of these MRI studies used a limited spatial coverage 
of the left ventricle with only three cardiac short- axis 
slices, possibly resulting in missed diseases and limited 
spatial resolution with a slice thickness in the order of 
several PET voxel sizes. Another major challenge for 
the clinical application of MRI is its use in patients with 
cardiac devices, which nevertheless can be done safely 
when the pacing is changed to asynchronous mode for 
pacing- dependent patients or to demand mode for other 
patients, and tachyarrhythmia functions are disabled113. 
This approach might even allow cardiac MRI in patients 
with pacemakers or defibrillators, with interpretability 
not being limited by artefacts31.
Future developments. Free- breathing perfusion MRI 
with subsequent motion correction will make the pro-
cedure easier for patients114. Improved detection of 
myocardial ischaemia is possible using the gradiento-
gram analysis, which has been validated in compari-
son with FFR115 (Fig. 5c). Although most quantitative 
imaging has focused on myocardial ischaemia owing 
to coronary obstructions, microvascular dysfunction 
including impairment of vessel compliance will be the 
focus of comprehensive cardiac MRI protocols. Given 
that microvascular dysfunction occurs diffusively and 
has a patchy distribution102, it can be differentiated from 
ischaemia caused by coronary obstructions using fractal 
analysis116 (Fig. 5c).
High- resolution, pixel- wise automated quantifica-
tion enables MBF to be measured on a pixel- by- pixel 
basis and microvascular disease to be distinguished 
from obstructive disease (Fig. 5d). The ability to visual-
ize subendocardial ischaemia, limiting partial volume 
effects and spatial averaging, is one of the main tech-
nical advantages of perfusion MRI, contributing to the 
elevated sensitivity of this method for the detection of 
ischaemia. Machine learning applied to myocardial per-
fusion MRI might improve quantification and, together 
with under- sampling, might reduce acquisition and 
reconstruction times27,117.
In summary, cardiac MRI is a comprehensive test to 
investigate myocardial perfusion, fibrosis and function. 
Several approaches to automating image acquisition, 
reconstruction and assessment will facilitate the clini-
cal implementation of myocardial perfusion MRI. 
As MRI does not require ionizing radiation, this modal-
ity is especially suited for use in young patients. On the 
basis of its characteristics, MRI should be considered in 
patients with complex disease who would benefit from 
imaging of function and fibrosis in addition to perfusion.
Key points for perfusion MRI. 
•	MRI avoids ionizing radiation and allows detailed 
characterization of myocardial tissue.
•	Challenges associated with MRI application include 
the increased prevalence of pacemakers31, the limited 
spatial coverage of the left ventricle32 and the need 
for a method for adequate determination of arterial 
input function.
•	Dedicated image- acquisition protocols (dual seq-
uence) or contrast agent injection schemes (dual 
bolus) are required for quantitative MRI perfusion 
analysis.
Fig. 5 | MRI for myocardial perfusion imaging. a | Imaging, processing and data 
analysis approaches in myocardial perfusion MRI. Standard multislice 2D MRI perfusion 
imaging yields image time series of dynamic myocardial signal change (Myo) during 
contrast agent bolus passage, allowing qualitative assessment of perfusion on the basis 
of eye- balling of hypoenhancing tissue (upper row). For semiquantitative analysis, the 
slopes of the dynamic magnetic resonance (MR) signal change during contrast passage 
are compared with the reduced slopes indicating ischaemic tissue (middle row). Using 
integrated arterial input function (AIF) measurements, which capture signal changes  
in the aortic outflow tract, and after conversion of dynamic MR signal changes to 
gadolinium (Gd) contrast agent concentrations, quantitative perfusion assessment  
can be performed, providing myocardial blood flow (MBF) values in units of millilitres 
per gram per minute. In conjunction with 3D MRI perfusion imaging, dynamic whole- 
 heart coverage without slice gaps is possible (lower row). b | Comparison of qualitative 
cardiovascular MR perfusion analysis versus SPECT, demonstrating improved diagnostic 
performance of cardiovascular MR (CMR) versus SPECT in 425 patients in the 
MR- IMPACT II trial108 (left panel). Comparison of quantitative multislice 2D MR perfusion 
analysis versus PET in 41 patients (middle panel) and in 21 patients (right panel) showing 
a significant correlation between the modalities and providing evidence of the clinical 
utility of quantitative MR perfusion imaging111,112. c | Gradientogram analysis allows the 
measurement of radial extent, temporal persistence, area, peak and average intensity  
as well as strength of the transmural perfusion gradient (left panels) for detection of 
obstructive coronary artery disease103. Fractal analysis enables pathophysiological 
differentiation of epicardial disease and microvascular disease (arrows; right panels).  
d | Examples of fully quantitative high- resolution MRI perfusion maps. From left to right: 
example of an individual with normal stress perfusion, with homogeneous perfusion 
values ranging from 3 to 4 ml/g/min; example of a patient with angina, smooth 
epicardial coronary arteries and diffusely reduced stress perfusion values and more 
severely impaired subendocardial perfusion; and example of a patient with two- vessel 
coronary artery disease, with severe transmural impaired stress perfusion in the right 
and left circumflex coronary artery perfusion territories. Part b left panel adapted from 
reF.108, CC BY 2.0 (https://creativecommons.org/licenses/by/2.0/). Part b middle panel 
adapted with permission from reF.111, Elsevier. Part b right panel adapted from reF.112, 
CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Part c left panels adapted 
with permission from reF.103, Wiley- VCH. Part d courtesy of C. Scannell, King’s College 
London, UK.
◀
  VOLUME 17 | JULY 2020 | 439NATURE REVIEWS | CARDIOLOGY
C O N S E N S U S  S TAT E M E N T
•	Automated voxel- wise quantification and dynamic 
3D, whole- heart MRI could improve the detailed 
and complete assessment of myocardial ischaemia.
•	 Evaluation of patients with complex disease is impro-
ved by the quantification of function, fibrosis and 
perfusion, and fractal analysis might allow obstructive 
and microvascular disease to be differentiated.
Echocardiography
Role in assessment of ischaemic heart disease. Echo-
cardiography, like MRI, avoids ionizing radiation but can 
be performed at the bedside. Contrast echocardiography 
using microbubble tracers improves image quality and 
reproducibility in the assessment of global and regional 
left ventricular function118,119. The microbubbles con-
sist of a gas core and typically a lipid or albumin shell. 
Ultrasound microbubbles remain entirely intravascu-
lar and can oscillate in resonance, producing the sig-
nals from individual microbubbles120. During infusion 
and steady state, signals emanating from microbub-
bles reflect the relative microvascular blood volume121. 
Microbubbles can be cleared from the myocardium by 
applying a series of high- power ultrasound pulses, and 
the myocardial replenishment is assessed by reverting 
to low- power imaging (Fig. 6a). This approach allows 
the myocardial blood velocity to be estimated as a semi-
quantitative measure of myocardial ischaemia121 both at 
rest and during stress (Fig. 6b). Echocardiography is the 
preferred technique in bedside situations, for instance in 
patients with suspected acute coronary syndrome, and 
can be useful in chronic myocardial ischaemia if good 
acoustic conditions are present. As collaterals supply 
blood to the myocardium, myocardial contrast echo-
cardiography allows quantitative assessment of MBF 
subtended by an occluded artery. An association exists 
between collateral blood flow and myocardial viability 
after a recent myocardial infarction, as shown by quan-
titative myocardial contrast echocardiography122, which 
also accurately detects multivessel disease123. Using 
vasodilator stress, hyperaemic flow can be assessed in 
each of the 16 segments of the left ventricle, and CFR is 
calculated by dividing hyperaemic MBF by MBF dur-
ing rest124. A good agreement has been shown between 
CFR measured by echocardiography and FFR, with the 
greatest discordance in symptomatic patients with nor-
mal FFR125. Echocardiography can also be used to assess 
viability in akinetic myocardial segments by assessing 
the microvasculature, which is present in viable but not 
necrotic tissue126.
Quantitative assessment of pathophysiology. Detailed 
technical characteristics of echocardiography are listed 
in Table 1. Quantitative assessment of myocardium per-
fusion can be achieved through destruction–reperfusion 
imaging and analysis of the time–intensity curves from 
different regions of interest in the myocardium (Fig. 6). 
Quantitative myocardial perfusion at rest has been 
shown to predict viable myocardium after myocardial 
infarction and in chronic coronary artery disease118. 
MBF reserve assessed during hyperaemic echocardiog-
raphy has been shown to be associated with the severity 
of coronary stenosis in patients with stable angina118. 
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Fig. 6 | Contrast echocardiography for myocardial perfusion imaging. a | Principle  
of destruction–replenishment imaging with the destruction pulse causing a flash in the 
image intensity at time zero. b | Time–intensity analysis in the region of interest shown as 
a dashed square in part a to derive estimates of myocardial blood flow (MBF). c | Clinical 
image showing multiple perfusion defects in the mid- septum, apex and right wall 
(arrows). d | An example of suboptimal image quality, which is an important challenge  
of echocardiography. Other important challenges include time- consuming, manual 
region- of- interest analysis and the limited acoustic window. e | An example of high frame 
rate contrast echocardiography acquired in the same patient as in part a, demonstrating 
its potential to improve image quality. MBFR , myocardial blood flow reserve.
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In a meta- analysis, MBF reserve had high accuracy for 
the prediction of flow- limiting coronary artery disease118 
and could be used to determine the pathophysiological 
basis of microcirculatory angina127.
Indications and clinical applications. Clinical indica-
tions for echocardiography are listed in detail in Fig. 2. 
Prospective studies including one randomized trial have 
investigated the use of contrast echocardiography for the 
detection of myocardial ischaemia (Fig. 6c) and its use for 
risk stratification of patients with known or suspected 
coronary artery disease, in both the acute and outpa-
tient settings128–132. However, reliable quantification of 
myocardial perfusion remains elusive and sometimes 
even qualitative assessment can be challenging133,134. 
This limitation is first and foremost owing to variabil-
ity in image quality (Fig. 6d). The common presence of 
noise and artefacts is an important factor that, in turn, 
affects the reproducibility of contrast echocardiography. 
This problem is particularly relevant for stress echocar-
diography, in which both high image quality and frame 
rates are required. In addition, limitations of the acoustic 
window can further diminish the signal- to- noise ratio. 
Echocardiography is ubiquitously available, is a bedside 
technique without ionizing radiation and is a preferred 
imaging technique among experienced operators in 
patients with acute chest pain.
Future developments. An important challenge for echo-
cardiography is the lack of automated quantifi cation 
techniques and software. Although various physi cal and 
human factors affecting quantification are known and can 
be accounted for135, automated myocardial segmenta-
tion remains challenging owing to speckle noise and 
3D deformations. Artificial intelligence solutions using 
machine learning for automated myocardial segmen-
tation on contrast echocardiography are being devel-
oped136. These techniques promise automated and fast 
segmentation and perfusion quantification. High frame 
rate ultrasonography with up to 6,000 frames per sec-
ond can be achieved through parallel data acquisition 
and digital beam forming. This approach offers image 
processing opportunities to increase the signal- to- noise 
ratio (Fig. 6c–e). High frame rate echocardiography can 
reveal the coronary microvasculature even without 
contrast but only in fairly shallow regions137. The fea-
sibility of high frame rate contrast echocardiog raphy 
for myocardial perfusion imaging in humans has been 
reported33. With this quantification, existing challenges 
might be addressed but its clinical utility needs further 
evaluation. In addi tion to high frame rate echocardiog-
raphy, new 3D imaging138 might help to address the 
clinical application challenges discussed above.
In summary, echocardiography is a readily availa-
ble bedside imaging test for which contrast- enhanced 
ultrasound applications using microbubbles have ena-
bled semiquantitative measures of perfusion. High frame 
rate ultrasonography might overcome the major image 
quality issues that are often present during echocardio-
graphy, such as low signal- to- noise ratio and artefacts. 
Automated segmentation and 3D imaging will facilitate 
echocardiography. On the basis of its characteristics, 
echocardiography should be considered when bedside 
imaging is required.
Key points for echocardiography. 
•	 Echocardiography is most commonly applied for car-
diac function imaging but is increasingly also being 
used for the assessment of myocardial perfusion and 
can be performed at the bedside.
•	The challenges of echocardiography include the com-
mon presence of noise and artefacts, lack of reproduc-
ibility, variable image quality and time- consuming 
manual analysis33.
•	High frame rate echocardiography allows the estima-
tion of myocardial blood velocity as a semiquantita-
tive measure of myocardial ischaemia with improved 
image quality.
•	Artificial intelligence solutions using machine learn-
ing for automated myocardial segmentation promise 
automated and fast segmentation and perfusion 
quantification.
•	 Evaluation of patients with suspected acute coronary 
syndrome at the bedside is the primary strength of 
echocardiography when performed by experienced 
operators.
Cardiac CT
Role in assessment of ischaemic heart disease. Cardiac 
CT is widely available with widespread clinical applica-
tion for noninvasive coronary angiography and has a 
class I (level of evidence B) recommendation in the 2019 
European guidelines, together with functional imaging, 
for use in individuals with a low- to- intermediate clinical 
likelihood of coronary artery disease4. However, stenosis 
grading by CT is limited in its capacity to predict ischae-
mia139, and CT perfusion imaging is not frequently used. 
For appropriate spatial coverage, >64 CT detector rows 
are recommended, while 256- row and 320-row CT pro-
vides whole-heart coverage in one heartbeat. For myocar-
dial CT perfusion imaging, static imaging either with or 
without a vasodilator stressor (such as adenosine) is used, 
whereas dynamic (4D) imaging allows the quantification 
of MBF but requires multiple scans over time. Dynamic 
CT perfusion imaging might provide the greatest clinical 
value but challenges with this modality include increased 
radiation dose, motion artefacts and image quality limi-
tations140. A meta-analysis showed higher sensitivity 
(0.85 versus 0.72) but lower specificity (0.81 versus 
0.90) for dynamic compared with static CT perfusion 
imaging141. The greatest role of CT in relation to myocardial 
ischaemia might be in stenosis and plaque quantification.
Quantitative assessment of pathophysiology. Detailed 
technical characteristics of CT are listed in Table 1. 
Advantages of CT include its high spatial resolution and 
the linear relationship between image attenuation, meas-
ured in Hounsfield units, and myocardial contrast agent 
concentration. Therefore, myocardial perfusion can, in 
principle, be measured quantitatively (absolute MBF)142 
(Fig. 7a) and/or semiquantitatively (static imaging)143,144.
Furthermore, microvascular disease in addition to col-
lateral circulation specifically in patients with occluded 
vessels can also be evaluated145,146. Although absolute 
  VOLUME 17 | JULY 2020 | 441NATURE REVIEWS | CARDIOLOGY
C O N S E N S U S  S TAT E M E N T
quantification of ischaemia is possible, the added value 
over semiquantitative assessment is uncertain147. Current 
CT scanners are challenged by beam- hardening arte-
facts, limited temporal resolution resulting in cardiac 
motion artefacts and low contrast- to- noise ratios. Beam- 
 hardening artefacts can be reduced using dedicated 
correction methods34–36. Temporal resolution can be 
improved by a higher rotation speed, dual- source CT 
or post- acquisition algorithms that estimate motion in 
order to compensate for it during image reconstruc-
tion37. Image acquisition during systole has the poten-
tial to improve CT perfusion image analysis, whereas 
β-blockers, which are often required for coronary CT 
angiography, might diminish the subsequent intended 
effects of vasodilator stressors148.
Indications and clinical applications. Cardiac CT has 
undergone exponential growth in the past decade, and 
clinical indications are listed in detail in Fig. 2. Coronary 
CT angiography is included in clinical guidelines as a 
diagnostic tool in stable patients with chest pain and an 
intermediate pretest probability of obstructive coronary 
artery disease1,3,4. However, in patients with heavily calci-
fied or stented coronary lesions, the addition of CT per-
fusion to CT angiography improves diagnostic accuracy 
from 71% to 87%149. Using combined CT angiography 
and CT perfusion might therefore reduce the number of 
unnecessary invasive coronary angiography procedures 
performed150,151. To identify patients in whom coronary 
revascularization might relieve myocardial ischaemia, 
myocardial CT perfusion imaging147 and computational 
fluid dynamics modelling to estimate FFR by CT have 
been investigated152,153. The international CORE320 
study154 was the first to demonstrate that the combi-
nation of static CT myocardial perfusion imaging and 
coronary CT angiography can correctly identify cor-
onary stenosis associated with myocardial ischaemia 
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Fig. 7 | CT for myocardial perfusion imaging. a | CT angiography showing a coronary stenosis in the left anterior 
descending coronary artery (top left) and the corresponding anterior myocardial perfusion defect during adenosine stress 
(top right)49. Time attenuation curve (bottom left) and left ventricular polar map of absolute myocardial blood flow (bottom 
right). b | Photon- counting energy- selective X- ray detectors show promise in improving quantification of tissue densities in 
CT and increased contrast- to- noise ratio (compared with standard CT perfusion). c | Machine learning using convolutional 
deep neural networks can generate high- quality images from low- dose CT acquisition and reduce image artefacts.  
FWHM, full- width at half- maximum.
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a meta- analysis155. Initial experience suggests that the 
combination of CT myocardial perfusion imaging 
and FFR estimated by CT can provide an even higher 
diagnostic accuracy, with an improvement in the AUC 
from 0.78 to 0.85 (reF.156). Importantly, computational 
fluid dynamics modelling to estimate FFR relies on 
mathematical assumptions and equal responses by 
the microcirculation to vasodilators. Moreover, and in 
contrast to invasive FFR, noninvasively estimated FFR 
does not account for collateral flow in the same man-
ner157. To what extent the implementation of CT–FFR 
will translate into improved patient outcomes still needs 
to be elucidated. Of note, a meta- analysis showed that 
CT perfusion has a higher specificity than CT–FFR 
(86% versus 78%)141. The randomized CATCH-2 trial158 
demonstrated that the addition of CT myocardial per-
fusion imaging to coronary CT angiography alone safely 
reduces the need for invasive examination and treatment 
(Fig. 7a). The CRESCENT II trial159 demonstrated the 
benefit of a tiered CT protocol with limited use of CT 
perfusion only if CT angiography shows a ≥50% ste-
nosis, which led to more appropriate revascularization 
indications than functional testing (88% versus 50%). 
In a two- centre study, semiquantitative static CT myo-
cardial perfusion imaging achieved a similar perfor-
mance to perfusion MRI compared with the reference 
standard of invasive angiography and SPECT160. This 
finding was supported in a meta- analysis, which showed 
similar negative likelihood ratios for perfusion imaging 
using PET, MRI or CT of 0.14, 0.14 and 0.12, respec-
tively73. Importantly, in the 2- year follow- up of the 
CORE320 study161, the combination of CT angiogra-
phy and semiquantitative CT perfusion showed similar 
accuracy in predicting cardiovascular events to invasive 
coro nary angiography and SPECT combined. In another 
single- centre study, MBF derived from dynamic CT per-
fusion had independent predictive value, with a hazard 
ratio of 5.7 when adjusted for obstructive coronary 
artery disease on CT angiography162.
Future developments. Two- compartment analysis 
might reduce underestimation of MBF by CT163,164, and 
the semiquantitative transmural perfusion ratio might 
improve diagnosis of myocardial ischaemia compared 
with using the MBF165. Low kilovolt scanning (70–80 kV) 
enables a substantial reduction in radiation dose, while 
increasing contrast- to- noise ratio166. New photon- 
counting energy- selective X- ray detectors are being 
developed for improved contrast and reduced radia-
tion dose167 (Fig. 7b). Algorithmic solutions will further 
improve contrast and reduce noise168. Four- dimensional, 
non- rigid motion correction will allow visual interpreta-
tion and pave the way for quantitative assessment of the 
2–3 billion voxels acquired during dynamic CT per-
fusion imaging169. Convolutional neural networks will 
reduce artefacts (Fig. 7c) by predicting high- quality 
images from low- dose CT170,171. Sparse- view CT is a 
futuristic way of reducing radiation dose in which the 
dose- emitting source is masked at different angular 
positions during gantry rotation. The resulting struc-
tured CT image artefacts might be corrected using deep 
neural networks26, and accurate scatter correction might 
become possible using deep learning, which is much 
faster than using Monte Carlo simulations172.
In summary, CT perfusion is rarely used but theor-
etically well suited for quantification of myocardial 
perfusion in addition to its capacity noninvasively to 
exclude obstructive coronary stenosis and to character-
ize coronary atherosclerosis173. Low kilovolt scanning, 
new CT detector technology and algorithmic solutions 
are promising approaches to reducing CT radiation dose 
and image artefacts. On the basis of these character-
istics, the greatest value of CT in relation to myocardial 
ischaemia is for the combined assessment of stenosis and 
atherosclerosis.
Key points for CT. 
•	CT perfusion imaging is not frequently used, whereas 
CT angiography offers highly accurate coronary 
angiography.
•	Challenges of cardiac CT include limited temporal 
resolution, beam and scatter artefacts, radiation dose 
and low contrast-to-noise ratios34–37.
•	CT systems with increased rotation speed, photon- 
counting energy-selective X-ray detectors and 
advanced machine learning technology, as well as 
two-compartment analysis could overcome the 
technological challenges.
•	The combined assessment of stenosis and character-
ization of atherosclerosis in relation to myocardial 
ischaemia promises the greatest clinical value but 
requires testing in trials.
•	 Evaluation of patients with insufficient angiographic 
image quality or borderline stenosis on coronary CT 
angiography might be improved with the use of 
CT for myocardial ischaemia.
Invasive coronary flow and pressure
Role in assessment of ischaemic heart disease. Invasive 
coronary physiology techniques have an increasing role 
in the clinical assessment of stenosis- induced myocar-
dial ischaemia. Their availability during catheteriza-
tion allows informed decision- making about coronary 
revascularization directly in the catheterization labora-
tory174. Invasive coronary flow and pressure measure-
ment is recommended in clinical guidelines to guide 
decision- making in the absence of noninvasive stress 
testing results1. To enable better decision- making in 
these situations, the advantages and limitations of cor-
onary physiology techniques in clinical practice must 
be recognized.
Quantitative assessment of pathophysiology. Detailed 
technical characteristics of invasive coronary flow and 
pressure measurement are listed in Table 1. The most 
widely adopted invasive approach to pathophysiology 
is (myocardial) FFR, which is calculated as the ratio of 
mean distal coronary pressure to mean aortic pressure 
during pharmacologically induced coronary vasodilata-
tion (Fig. 8a). The aim of FFR is to quantify the impair-
ment of maximal coronary flow induced by a stenosis 
from invasive coronary pressure measurement175. FFR- 
guided coronary interventions substantially reduce the 
need for revascularization procedures compared with 
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decision- making by visual assessment alone and leads 
to similar long- term clinical outcomes176. However, two 
important issues remain. First, the adoption of FFR 
guidance remains limited to <6% of patients in most 
countries globally, with only a few exceptions38. This 
situ ation is in stark contrast to clinical guidelines, which 
advocate the widespread use of invasive coronary meas-
urements. Furthermore, noninvasive ischaemia imaging 
tests are used in only 64% of all patients before coronary 
angiography150,151. Second, the prognostic value of FFR 
in patients with stenoses and an abnormal FFR is limi-
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Fig. 8 | Invasive coronary flow and pressure measurement. a | Representation of the ratio of resting distal coronary 
pressure (Pd) to aortic pressure (Pa), instantaneous wave- free ratio (iFR), fractional flow reserve (FFR) and coronary flow 
reserve (CFR) calculation from invasively assessed coronary pressure or flow measurement. b | Agreement between 
coronary pressure (FFR or iFR) and CFR measurement. Discordance between FFR and CFR occurs in 30–40% of individuals, 
whereas better agreement can be observed between iFR and CFR . c | Interpretation of combined FFR and CFR 
measurement and its effect on clinical outcome193. Four main quadrants can be identified by the clinical cut- off values  
for FFR and CFR , indicated by the dashed lines. Patients in the upper right area (blue) have normal FFR and CFR; patients 
in the lower left area (red) have abnormal FFR and CFR; patients in the upper left area (orange) have abnormal FFR  
and normal CFR; and patients in the lower right area (green) have normal FFR and abnormal CFR , which indicates 
predominant microvascular involvement or diffuse coronary artery disease. Patients in the small dark green region in the 
lower right have an FFR close to 1 and an abnormal CFR , indicating sole involvement of the coronary microvasculature. 
The prognostic value of FFR and CFR in terms of major adverse cardiovascular events (MACE) is shown on the right.  
Part c adapted with permission from reF.193, van de Hoef, T. P. et al. Physiological basis and long- term clinical outcome  
of discordance between fractional flow reserve and coronary flow velocity reserve in coronary stenoses of intermediate 
severity. Circ. Cardiovasc. Interv. 7(3), 301–311 (https://www.ahajournals.org/journal/circinterventions).
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therapy alone having a cardiovascular event within 
5 years39. This finding calls into question the clinical 
practice guidelines advocating revascularization in all 
vessels with an abnormal FFR1. The limited adoption of 
FFR is related to practical and economic issues as the 
procedure is both time- consuming and costly. Some of 
these problems can be addressed by the use of simpler 
measurements, such as the instantaneous wave-free 
ratio (iFR) or resting distal coronary- to- aortic press-
ure ratio (Pd/Pa). iFR is defined as the ratio of distal cor-
onary pressure to aortic pressure at a distinct time in 
cardiac diastole, termed the wave- free period (Fig. 8a), 
in resting, non- vasodilated conditions177. The diagnostic 
efficiency of FFR and iFR for haemodynamically signi-
ficant coronary stenoses is similar to that of SPECT 
or PET38. Moreover, an iFR- guided revascularization 
strategy has been documented to provide equivalent 
clinical outcomes to those of an FFR- guided strategy in 
two large randomized clinical trials, where fewer coro-
nary revascularization procedures were indicated in the 
iFR- guided treatment groups178,179.
Importantly, pressure- based measurements provide 
an estimate of stenosis- induced flow impairment, but 
they are different from coronary flow or CFR, which 
determine ischaemia. CFR is defined as the ratio of cor-
onary flow during pharmacological vasodilatation to 
flow at rest (Fig. 8a), representing the reserve capacity of 
the coronary circulation to increase flow in response to 
increased demand. A lower CFR is linked to symptoms 
of ischaemia and is predictive of myocardial infarction 
and death. A challenge is that coronary pressure- derived 
estimates of flow impairment do not correlate with meas-
ured CFR in 30–40% of patients132,133 (Fig. 8b). This situa-
tion arises because physiology dictates that an increase 
in coronary flow leads to lower (abnormal) FFR but 
higher (normal) CFR and vice versa180. This observation 
suggests that combined FFR and CFR is better for iden-
tifying the individual pathophysiology and predicting 
clinical outcomes132 (Fig. 8c).
FFR and iFR are considered to estimate the effect 
of the stenosis on distal MBF, thereby taking into account 
the effect of collateral flow to the myocardium of inter-
est. For FFR, coronary FFR can be calculated, which is 
the FFR in the coronary artery when excluding the effect 
of collateral flow. However, myocardial FFR has been 
studied in clinical outcome trials and is used in daily 
clinical practice. Nonetheless, coronary collateral flow 
can be assessed directly using invasive coronary pres-
sure and flow measurements in several ways. Coronary 
wedge pressure, which is the distal coronary pressure 
obtained during occlusion of the epicardial coronary 
artery to prevent antegrade coronary flow, is a simple 
marker of collateral function. Furthermore, collateral 
blood flow can be quantified in more detail using either 
flow velocity or coronary pressure measurements. The 
Doppler velocity- derived collateral flow index (CFI) is 
calculated as the intracoronary flow velocity integral 
(CFVI) during balloon occlusion as a fraction of CFVI 
during coronary patency. The coronary pressure- derived 
CFI (CFIp; also called collateral FFR) is calculated as 
the coronary wedge pressure minus venous back pres-
sure as a fraction of the aortic pressure minus venous 
back pressure. When both Doppler velocity and coro-
nary pressure measurements are performed, the total 
collateral resistance can also be calculated, as well as 
the individual resistances in the components of the col-
lateral pathway. CFI and CFIp are the most applicable 
techniques, and values of >0.30 are generally considered 
to indicate adequate collateral artery function, substan-
tiated by the absence of angina or electrocardiogram 
changes during balloon occlusion181.
Indications and clinical applications. Clinical indica-
tions for invasive approaches are listed in detail in Fig. 2. 
In patients with a high likelihood of invasive treatment 
being required, invasive coronary flow and pressure 
measurement is well suited to guide treatment decision- 
making, with FFR having achieved greatest acceptance 
but limited clinical uptake38. This situation might be 
improved using less complex invasive measurements, 
such as iFR, which compared with an FFR- guided strat-
egy leads to fewer revascularizations while providing 
equivalent 1- year clinical outcomes178,179. Resting Pd/Pa 
has so far been investigated only in diagnostic studies 
and has shown similar accuracy to iFR182. Considering the 
limitations of coronary pressure- based techniques, 
the decision to revascularize should optimally be on the 
basis of the combination of imaging ischaemia tests and 
coronary pressure measurement, the results of which 
should be interpreted in relation to the symptoms of the 
individual patient to determine the risk–benefit ratio of 
a coronary intervention.
Future developments. The suboptimal discriminative 
value of FFR can be addressed by the (additional) direct 
measurement of coronary flow, instead of its estimation 
from coronary pressure measurement180. This approach 
is currently being evaluated in a multicentre setting in 
the DEFINE- FLOW study183. Meanwhile, it is impor-
tant to realize that the current technology for direct flow 
measurement is fairly outdated and technically demand-
ing, and substantial technical revisions are expected 
shortly. However, current ischaemia- guided or coronary 
pressure- guided coronary interventions are already supe-
rior to angiography- based decision- making alone176,178,179. 
Artificial intelligence, mainly in the form of machine 
learning and intelligent algorithms, is increasingly being 
recognized as a tool to aid invasive diagnostics184 and to 
improve the safety and accuracy of invasive physiology 
techniques. Examples are the automated interpretation 
of aortic pressure traces and iFR pullback traces to iden-
tify inaccurate pressure readings that might influence 
FFR and/or iFR values or their interpretation and affect 
decision- making.
In summary, FFR measurements can substantially 
reduce the need for revascularization compared with 
visual assessment alone, without impairing long- term 
clinical outcomes. However, the limited uptake of inva-
sive measurement of FFR in clinical practice is related 
to the complexity of the procedure, which can be over-
come using measurement of iFR and Pd/Pa. The com-
bined measurement of pressure and flow should have 
the highest discriminative capacity and prognostic 
value but requires further testing. On the basis of their 
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characteristics, invasive measurements have the great-
est value in patients with a high likelihood of requiring 
invasive treatment.
Key points for invasive coronary flow and pressure 
measurement. 
•	 Invasive catheter- based methods can be used to 
measure coronary flow and pressure.
•	Challenges of invasive coronary flow and pressure 
measurements include the diagnostic and prognostic 
characteristics of FFR, the complexity of the proce-
dure and its limited uptake in clinical practice (used 
in <6% of patients38,39).
•	 iFR and resting Pd/Pa are simpler than FFR but have 
similar prognostic and diagnostic value and might 
improve the clinical uptake of coronary pressure 
measurements.
•	The combined assessment of CFR and FFR prom-
ises the greatest discriminative value for individual 
pathophysiology but requires testing in trials.
•	 In patients with a high likelihood of requiring inva-
sive treatment, invasive coronary flow and pres-
sure measurement is well suited to guide treatment 
decision- making.
•	 Invasive coronary pressure and flow measurements 
allow coronary collateral function to be quantified.
•	Artificial intelligence might further improve the accu-
racy and interpretation of coronary pressure readings 
and could improve coronary flow assessment.
Conclusions
Current cardiac imaging modalities offer widespread 
utility to assess myocardial ischaemia quantitatively, 
without the risks of invasive investigation. Among the 
myocardial perfusion imaging tests, PET is the reference 
standard for quantification, and SPECT is most com-
monly used. Although MRI is less commonly used than 
SPECT, MRI avoids ionizing radiation, as does echocar-
diography. Echocardiography has similar advantages 
to those of MRI and can be performed at the bedside. 
CT is not frequently used for perfusion imaging but 
offers coronary angiography including assessment of 
plaque burden and can provide a geometric framework 
for model- based estimation of CT–FFR. Intracoronary 
measurements of pressure and flow velocity provide 
comprehensive haemodynamic information to guide 
invasive treatment. All six ischaemia imaging techniques 
have distinct advantages and disadvantages (Table 1).
The diagnostic potential of these imaging techniques 
is substantially improved by technical advances that can 
yield quantitative measures of myocardial perfusion. 
Dedicated cardiac SPECT cameras have emerged for 
improved sensitivity and resolution at lower doses of 
radiation, and dynamic imaging enables compartmental 
modelling and thereby provides absolute measures of 
myocardial ischaemia. Small cyclotrons and the avail-
ability of 18F- labelled PET tracers could improve logis-
tics, and hybrid PET–CT might provide comprehensive 
assessment, especially in patients with multivessel 
disease. Automated voxel- wise perfusion quantifica-
tion of whole- heart MRI could improve the assessment 
of myocardial ischaemia to facilitate the evaluation of 
patients with complex disease and the differentiation 
between obstructive and microvascular disease. High 
frame rate echocardiography allows the estimation of 
myocardial blood velocity with improved image qual-
ity, and machine learning can be used for automated 
and fast myocardial segmentation. CT with increased 
rotation speed, photon- counting detectors and machine 
learning could overcome temporal resolution challenges, 
beam and scatter artefacts, and low contrast- to- noise 
ratios of CT perfusion imaging for use in patients 
with borderline coronary stenosis on CT angiography. 
Invasive coronary measurements of iFR and resting Pd/Pa 
is simpler than measurement of FFR but have similar 
prognostic and diagnostic value and might improve the 
so- far limited uptake of coronary pressure measure-
ments. The combined assessment of CFR and FFR pro-
vides the greatest promise in discriminating individual 
pathophysiologies.
No single quantitative perfusion imaging technique is 
best for all types of patient, for all disease stages or at all 
clinical centres, as usage also depends on the availability 
of local expertise. Using a Delphi consensus process, we 
have identified the most appropriate clinical scenario 
for each diagnostic test for myocardial ischaemia (Fig. 2). 
SPECT with the use of new detectors allows quantifi-
cation of MBF and is also suited to quantification in 
patients with a high BMI. PET should be the primary 
test in patients with multivessel disease to confirm or 
exclude balanced ischaemia. MRI allows the evaluation 
of patients with complex disease who would benefit from 
imaging of cardiac function and myocardial fibrosis in 
addition to perfusion. Echocardiography is the preferred 
technique for assessing acute coronary syndrome in 
bedside situations. CT has greatest value for combined 
quantification of stenosis and characterization of athero-
sclerosis in relation to myocardial ischaemia. In patients 
with a high likelihood of requiring invasive treatment, 
invasive coronary flow and pressure measurement is well 
suited to guide treatment decision- making.
All imaging modalities share the requirement to take 
coronary pathophysiology into account in the interpreta-
tion of noninvasive perfusion imaging and invasive coro-
nary pressure and flow data. Quantification of myocardial 
perfusion by imaging can provide accurate measures of 
the burden of ischaemia to determine individualized 
treatment strategies. This assessment is very important 
because the ORBITA study134 showed that a much more 
comprehensive, pre- catheterization, quantitative, multi-
modality imaging strategy is required in patients with 
suspected ischaemia. This approach helps to identify the 
most appropriate treatment strategy with or without cor-
onary revascularization and might translate into lower 
morbidity and mortality. Therefore, in the time of per-
sonalized medicine, perfusion imaging provides robust, 
quantitative assessment of myocardial ischaemia that can 
be used to guide individual risk stratification and direct 
treatment decision- making. Future studies will incor-
porate the emerging computational support of machine 
learning to benefit complex decision- making about the 
need for coronary revascularization.
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